Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Kathy Oubre, on cancer patients being given home infusions of treatments during the COVID-19 pandemic

Kathy Oubre, Chief Operations Officer, Pontchartrain Cancer Center, shares opinion on whether cancer patients can be given home infusions of cancer treatments during the COVID-19 pandemic

Tags: COA Conference CoveragePatient Care (includes Supportive Care, Palliative Care, Survivorship, QOL, Advocacy, Adverse Events, Pain Management)Personalized Oncology (includes Cancer Genetics)

Published: 29 April 2020

Recent Videos: Personalized Oncology (includes Cancer Genetics)

There have been no new videos in this category within the last 12 months.

Related Videos

video-image

Martin Dietrich, MD, PhD, explains ordering Genomic Profiling (CPG) tests in the community oncology setting and the timeline of test results

video-image

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

video-image

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

video-image

Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma

video-image

Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Jonathan Hirsch, discusses how precision medicine is being used to help improve cancer treatment

video-image

Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials

video-image

Bobby Green, MD, discusses collaboration efforts between Flatiron and Foundation Medicine

video-image

Bobby Green, MD, on leveraging genomic testing into actionable data

video-image

Kathy Oubre, MS, considers how comfortable physicians and payers are with biosimilars

video-image

Kathy Oubre, MS, speculates on the future of biosimilars

video-image

Kathy Oubre, MS, offers opinion on whether biosimilars are living up to their estimated cost savings

video-image

Kathy Oubre, MS, comments on the recent criticism regarding the use of biosimilars

video-image

Bo Gamble, on the most important critical success factors when adopting a new payment model

video-image

Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care

video-image

Bo Gamble, discusses the impact of consolidation on the delivery of cancer care

video-image

Bo Gamble, speculates on the future of alternative payment models (APMs)

video-image

Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape

video-image

Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care

video-image

Bo Gamble, considers how value & quality may vary across community oncology practices

video-image

Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care

video-image

Alti Rahman, MHA\MBA, CSSBB, considers how oncology practices can reduce costs & maximize savings

video-image

Alti Rahman, MHA\MBA, CSSBB, provides perspective on the challenges facing oncology practices

video-image

Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists

video-image

Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology

video-image

Johnetta Blakely, MD, elaborates on how HEOR may be used in conjunction with real-world evidence

video-image

Johnetta Blakely, MD, considers how HEOR data influences payer decisions

video-image

Johnetta Blakely, MD, explains the role of HEOR as it contributes to value-based care

video-image

Jonathan E. Levitt, Esq., considers how PBM behaviors are changing as a result of the pandemic

video-image

Jonathan E. Levitt, Esq., offers opinion on PBM consolidation & the changing dynamics of cancer care

video-image

Jonathan E. Levitt, Esq., explains how copay aggregators differ across PBMs

video-image

Jonathan E. Levitt, Esq., on the experience of hem/onc groups unable to enter into a PBM network

video-image

Jonathan E. Levitt, Esq., explains how DIR fees impact practice costs and efficiencies

video-image

Jonathan E. Levitt, Esq., discusses the state of payer mandates for white / brown bagging

video-image

Sara Riordan, MS, CGC, on the role of genetic counselors as part of a multidisciplinary cancer team

video-image

Sara Riordan, MS, CGC, regarding the significance of biomarker testing in early-stage cancer

video-image

Sara Riordan, MS, CGC, on how genetic signature & biomarker tests are used in cancer management

video-image

Sara Riordan, MS, CGC, elaborates on the unmet needs in biomarker testing

video-image

Lalan S. Wilfong, MD, discusses key takeaways from the 2021 Virtual Community Oncology Conference

video-image

Lalan S. Wilfong, MD, regarding the impact of geographic location on the delivery of cancer care

video-image

Lalan S. Wilfong, MD, considers the impact of the Oncology Care First model

video-image

Lalan S. Wilfong, MD, offers opinion on the key success factors for new payment reform models

video-image

Lalan S. Wilfong, MD, speculates on the future of oncology medical homes

video-image

Sibel Blau, MD, shares how QCCA has reached their goals in spite of COVID-19

video-image

Sibel Blau, MD, discusses the impact of COVID-19 on cancer screenings

video-image

Sibel Blau, MD, speculates on the role of telehealth in cancer management

video-image

Sibel Blau, MD, regarding the greatest challenges in treating cancer patients during COVID-19

video-image

Sibel Blau, MD, considers what we've learned about managing cancer patients during COVID-19

video-image

Derek Raghavan, MD, examines the projected cost of new GNRH antagonist therapy and its implications

video-image

Marcia Brose, MD, PhD, provides opinion on who should be tested TRK fusions

video-image

Marcia Brose, MD, PhD, expounds on what should be done for patients who progress on larotrectinib

video-image

Marcia Brose, MD, PhD, on biopsy requirements for optimal evaluation for actionable TRK fusions

video-image

Marcia Brose, MD, PhD, describes how testing for TRK abnormalities are accomplished

video-image

Marcia Brose, MD, PhD, discusses the dosing, safety and efficacy of larotrectinib reported at ASCO20

video-image

Marcia Brose, MD, PhD, provides an overview of TRK fusion treatment in cancer patients

video-image

Daneng Li, MD, on the study results investigating the geriatric assessment tool & chemo side effects

video-image

Daneng Li, MD, describes the geriatric assessment tool developed at City of Hope

video-image

Bruce Feinberg DO, explains strategies that are or should be provided for managing cancer survivors

video-image

Bruce Feinberg, DO, provides examples of social determinants of health and how they qualify as this

video-image

Bruce Feinberg, DO, discusses the importance of social determinants to the health of cancer patients' outcomes

video-image

Sankalp Sethi & Jeffrey Patton, MD, on how pharma can help community oncology’s COVID-19 challenges

video-image

Sankalp Sethi and Jeffrey Vacirca, MD, FACP, examine partnering with pharma during COVID-19

video-image

Bruce Feinberg, DO, on the understanding medical oncologists have on social determinants of health

video-image

Dinesh Kapur, MD, explains why his practice eventually decided to join OneOncology

video-image

Dinesh Kapur, MD, describes how OneOncology welcomed his group and impressive treatment resources

video-image

Dinesh Kapur, MD, provides thoughts on early impressions of CMMI and the Oncology Care First model

video-image

Dinesh Kapur, MD, shares thoughts on OCM reducing the cost of care and status of the quality

video-image

Robert J. Brooks, MD, offers advantages and disadvantages of joining a large oncology group

video-image

Robert J. Brooks, MD, advises oncology practices that are considering whether to stay independent or to join a larger group of oncologists

video-image

Robert J. Brooks, MD, describes how OneOncology has welcomed his group and impressive resources that help treat cancer patients

video-image

Stephen M. Schleicher, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

video-image

Stephen M. Schleicher, MD, MBA, describes how the cost of drugs are impacting the effectiveness of APMs

video-image

Sibel Blau, MD, shares examples of applied informatics being incorporated into patient management

video-image

Sibel Blau, MD, on the improvement of care via AI, especially in high risk cancer patients

video-image

Sibel Blau, MD, expounds upon maintaining quality care with non-clinical staff working remotely

video-image

Kathy Oubre, describes robotic process automation and how it is helping with prior authorization

video-image

Kathy Oubre, details how creating tailored patient education has enhanced patient/provider relationships

video-image

Kathy Oubre, considers the predicted surge in cancer patients after the COVID-19 pandemic

video-image

Kathy Oubre, offers best practices and new programs being implemented to safely treat patients during the COVID-19 pandemic

video-image

Debra Patt, MD, on how applied informatics is being incorporated into cancer patient management

video-image

Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

video-image

Debra Patt, MD, offers opinion on whether embracing informatics is worth the financial investment

video-image

Jeffrey Patton, MD, expounds upon maintaining quality care with non-clinical staff working remotely

video-image

Jeffrey Patton, MD, anticipates whether smaller practices will be able to survive the pandemic or if they are in danger of closing due to lack of resources

video-image

Jeffrey Patton, MD, describes his care team's strengths during this pandemic and habits to continue post pandemic

video-image

Jeffrey Patton, MD, provides thoughts regarding the future of cancer care amidst a national crisis and providing quality cancer care across the country

video-image

Jeffrey Patton, MD, recalls barriers to overcome when treating patients with cancer during the COVID-19 pandemic

video-image

Steven D'Amato, RPH, BSPharm, on the adoption of telemedicine and its impact on the patient/provider relationship

video-image

Steven D'Amato, RPH, BSPharm, describes best practices and new programs being adopted to treat patients during the COVID-19 pandemic

video-image

Steven D'Amato, RPH, BSPharm, on his team's strength as a result of the pandemic and habits to continue

video-image

Alti Rahman, MHA, MBA, on how robotic process automation aids with prior authorizations in his practice

video-image

Alti Rahman, MHA, MBA, offers an assessment of prior authorizations during the COVID-19 pandemic

video-image

Alti Rahman, MHA, MBA, explains the adoption of telemedicine and reimbursement expectations

video-image

Nick Recker, on the effectiveness of interoperability between telehealth platforms and oncology EMRs

video-image

Nick Recker, explains how successful oncology practices integrate telehealth beyond the COVID-19 pandemic

video-image

Nick Recker, shares issues facing practices as they rush to integrate telehealth into practice operations

video-image

Nick Recker, describes the role telehealth has played for healthcare providers during this current COVID-19 pandemic

video-image

Bo Gamble, describes the most common mistakes that practices make when coding for oncology treatment

video-image

Bo Gamble, expands on the practice coding problem and repercussions of improper coding

video-image

Bo Gamble, recommends best practices regarding proper coding for oncology practices

video-image

Bo Gamble, illustrates how practices are dealing with adding new CMS telehealth/telemedicine in the midst of the COVID-19 pandemic

video-image

Bo Gamble, shares concerns on the coding changes coming in 2021 and the impact impact they may have on community oncology

video-image

Antonio Ciaccia, expresses advantages Pharmacy Benefit Managers may bring to the healthcare system

video-image

Antonio Ciaccia, demonstrates how Pharmacy Benefit Managers are gaming the healthcare system

video-image

Antonio Ciaccia, explains how smaller pharmacies compete with PBMs and how they are being priced out

video-image

Antonio Ciaccia, on changes that need to be made on a national level that would bring Pharmacy Benefit Managers (PBMs) more in line with the interests of cancer patients and payers

video-image

Martin Dietrich, MD, PhD, provides thoughts on how socioeconomic factors affect on access to Comprehensive Genomic Profiling (CGP) tests and subsequent decision making

video-image

Martin Dietrich MD, PhD, offers resources to aid decision making after receiving Comprehensive Genomic Profiling tests results

video-image

Martin Dietrich, MD, shares concerns about the validity of Comprehensive Genomic Profiling tests and patient decision making

video-image

Martin Dietrich, MD, PhD, describes a Comprehensive Genomic Profiling test, when it should be ordered, and information the test results provides

video-image

Kashyap Patel, MD, recalls his practice's adaption to OCM 1.0 and further adaption to OCM 2.0

video-image

Kashyap Patel, MD, updates us on the stance of OCM 2.0 as of the annual COA meeting 2020

video-image

Kashyap Patel, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

video-image

Kashyap Patel, MD, expresses early impressions of CMMI and the Oncology Care First (OCF) model

video-image

Thomas Sonderberg, expresses opinion on components of care that are essential for employers to consider as part of their comprehensive coverage of their employees

video-image

Thomas Sonderberg, on the needs of small to midsize employers compared to larger employers with more contract leverage

video-image

Thomas Sonderberg, provides concerns of an employer coverage of cancer care and also the good news in cancer care

video-image

Thomas Sonderberg, describes the scope of cancer care cost to an employer and variations in coverage by types of employer

video-image

Stephen M. Schleicher, MD, MBA, on early impressions of CMMI and the Oncology Care First (OCF) model

video-image

Dinesh Kapur, MD, expresses changes in Eastern Connecticut Hematology Oncology amidst the COVID-19 pandemic

video-image

Sibel Blau, MD, describes her care team's strength while embracing new communications and technology in the midst of the COVID-19 pandemic

video-image

Steven D'Amato, RPh, BScPharm, on maintaining quality of care with non-clinical staff working remotely and the steps being taken to support this situation

video-image

Jeffrey Patton, MD, elaborates on critical success factors for providing quality cancer care during the COVID-19 pandemic

video-image

Debra Patt, MD, on how informatics work with physicians to aid in treatment decision making at the point of care

video-image

Thomas Sonderberg, describes challenges that employers face managing cancer care costs and the price of drugs

video-image

Bo Gamble, expounds on new services and associated codes that are important in the era of payment reform

video-image

Alti Rahman, MHA, MBA, shares examples of new practices being implemented to safely treat cancer patients through the COVID-19 pandemic

video-image

Nick Recker, comments on security issues related to rapid adoption of Telehealth in oncology practices

video-image

Antonio Ciaccia, describes pitfalls oncology practices need to know when prescribing a specialty cancer drug at a Pharmacy Benefit Managers-owned pharmacy

video-image

Martin Dietrich, MD, PhD, provides examples of how genetic profile tests are being used to make decisions on patient care

video-image

Kashyap Patel, MD, describes whether quality of care has suffered or improved as OCM reduces the cost of cancer care

video-image

Jeff Vacirca, MD, discusses the capabilities of OneOncology's IT system

video-image

Dan Wygal on how benefit design & value based contracting may make cancer drugs more affordable

video-image

Jeff Vacirca, MD, explains the synergy between three cancer centers that make up OneOncology

video-image

Dan Wygal explains what AstraZeneca is doing to help make cancer drugs more accessible for patients

video-image

Jeff Vacirca, MD, explains why OneOncology is a unique practice model

video-image

Dan Wygal provides perspective on value-based contracting in oncology

video-image

Jeff Vacirca, MD, regarding the novel practice models presented at COA 2019

video-image

Jax Zummo outlines some of the concerns with value-based contracting

video-image

Jax Zummo explains how value-based contracting works

video-image

Jax Zummo provides opinion on how the pharmaceutical industry is helping community oncology

video-image

Lee Schwartzberg, MD, explains the key drivers of success for OneOncology

video-image

Michael Schuh, BS, PharmD, MBA, discusses the latest advances in integrative medicine

video-image

Robin Shah considers how OneOncology is poised for growth

video-image

Lee Schwartzberg, MD, shares his goals as medical director of OneOncology

video-image

Michael Schuh, BS, PharmD, MBA, regarding supplements and integrative medicine in cancer care

video-image

Jax Zummo provides perspective on the rising cost of cancer drugs and patient access

video-image

Robin Shah regarding the capabilities of OneAnalytics

video-image

Lee Schwartzberg, MD, on how step therapy & utilization management are impacting community oncology

video-image

Michael Schuh, BS, PharmD, MBA, elaborates on integrative medicine

video-image

Jeff Patton, MD, considers whether OneOncology is open to growth in new markets

video-image

Kashyap Patel, MD, tells us how tele-medicine is changing the way cancer treatment is delivered

video-image

Christine Pfaff, RPh, explains how medically-integrated pharmacies improve cancer care

video-image

Jeff Patton, MD, shares details regarding OneOncology's advanced IT platform

video-image

Debra Patt, MD, evaluates the aggregation trends in community oncology

video-image

Kashyap Patel, MD, regarding two-sided risk and participation in the OCM

video-image

Christine Pfaff, RPh, discusses the challenges associated with medically-integrated pharmacies

video-image

Jeff Patton, MD, regarding key drivers of success for OneOncology

video-image

Debra Patt, MD, on why it is important for community oncologists to partner with associations

video-image

Kashyap Patel, MD, explains how practices can leverage data to negotiate stronger payer contracts

video-image

Christine Pfaff, RPh, explains why cancer centers should embrace medically-integrated pharmacies

video-image

Jeff Patton, MD, on why community oncologists should embrace novel practice models

video-image

Debra Patt, MD, regarding important policy updates coming out of COA 2019

video-image

Kashyap Patel, MD, offers opinion on novel practice models

video-image

Christine Pfaff, RPh, on how COPA is helping community oncology manage their dispensing pharmacies

video-image

Jeff Patton, MD, considers some of the important challenges & solutions for community oncology

video-image

Debra Patt, MD, shares some of the important takeaways from the 2019 COA Conference

video-image

Kashyap Patel, MD, discusses keys to success for today's oncology practices

video-image

Sonia Oskouei, PharmD, DPLA, elaborates on the reimbursement challenges facing biosimilars

video-image

Sonia Oskouei, PharmD, DPLA, speculates on the future of biosimilars

video-image

Ted Okon reflects on past victories for COA and speculates on future progress

video-image

Sonia Oskouei, PharmD, DPLA, on the clinical challenges associated with the adoption of biosimilars

video-image

Ted Okon on what community oncologists should know about the recent PBM hearings

video-image

Sonia Oskouei, PharmD, DPLA, on the differences between approval for biologics & biosimilars

video-image

Ted Okon on the scope of the step therapy & utilization management concern for community oncologists

video-image

Jonathan Levitt explains how DIR fees are impacting community oncology

video-image

Ted Okon on whether there is a disconnect between policy & the realities of community oncology

video-image

Jonathan Levitt considers how state legislation regarding community oncology has changed

video-image

John Frownfelter, MD, FACP, on how AI is bringing about a better understanding of the cancer patient

video-image

Jonathan Levitt on what has happened in the last 6 months with PBMs & state Medicaids

video-image

John Frownfelter, MD, FACP, outlines some of the hurdles AI has introduced into clinical practice

video-image

Ben Jones considers recent policy changes of which oncologists should be aware

video-image

John Frownfelter, MD, FACP, explains how artificial intelligence is contributing to value-based care

video-image

Ben Jones offers his opinion on priority policy concerns

video-image

John Frownfelter, MD, FACP, explains how artificial intelligence is being applied to cancer care

video-image

Nicolas Ferreyros, on the influence of pharmacy benefit managers

video-image

Ira Klein, MD, MBA, FACP, on embracing value-based oncology care

video-image

Nicolas Ferreyros, on what oncologists should know about their federal policymakers

video-image

Ira Klein, MD, MBA, FACP, provides perspective on the rising cost of cancer drugs

video-image

Nicolas Ferreyros, explains why oncologists should communicate with their local representatives

video-image

Ira Klein, MD, MBA, FACP, on the role of value in cancer drug development

video-image

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

video-image

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

video-image

Anshu Jain, MD, tells us what physicians & payers should know about proton therapy

video-image

Melissa Johnson, MD, on the updated NCCN guidelines in regards to PD-L1 testing

video-image

Anshu Jain, MD, on the current controversy regarding proton therapy in cancer care

video-image

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

video-image

Anshu Jain, MD, explains why proton therapy is important in terms of delivery & outcomes

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares how COA is supporting Dayton Physicians Network

video-image

Matthew Hall, MD, tells us what physicians & payers should know about proton therapy

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares key takeaways from the 2019 COA Annual Conference

video-image

Matthew Hall, MD, considers whether the application of proton therapy is growing

video-image

Lakshmi Aggarwal, MD, explains why transparency is necessary in the healthcare system

video-image

Matthew Hall, MD, on the difference between photon therapy & proton therapy

video-image

Lakshmi Aggarwal, MD, considers the role of politics in oncology

video-image

Lucio Gordan, MD, shares how the shift in site of care is impacting community oncology

video-image

Lakshmi Aggarwal, MD, offers opinion on the evolving landscape of oncology

video-image

Lucio Gordan, MD, explains how practices should leverage their OCM performance data

video-image

Jesse Dresser evaluates the impact of payer trends on drug manufacturers' market access strategy

video-image

Lucio Gordan, MD, on best practices in delivering value-based care

video-image

Jesse Dresser shares what legal tools are available to dispensing oncology practices & pharmacies

video-image

Lucio Gordan, MD, describes the primary drivers of the cost of cancer care

video-image

Jesse Dresser considers the challenges for dispensing oncology practices regarding payer networks

video-image

Kathy Gaughran explains how Healthcare Success is helping community oncologists

video-image

Jesse Dresser on the trends he is observing between payers and dispensing practices & pharmacies

video-image

Bobbi Buell, MBA, regarding the biggest changes & challenges in oncology reimbursement in 2019

video-image

Sibel Blau, MD, on the pros & cons associated with participation in a clinically integrated network

video-image

Sean Brusky explains how the pharmaceutical industry is working to help community oncology

video-image

Sibel Blau, MD, elaborates on clinically integrated networks

video-image

Sean Brusky provides Genentech’s perspective on the rising cost of cancer drugs and patient access

video-image

Sibel Blau, MD, tells us more about IQ Oncology

video-image

Sean Brusky on taking value into consideration when developing cancer drugs

video-image

Sibel Blau, MD, shares what the QCCAN is doing for participating members

video-image

Michael Diaz, MD, on how community oncology is shaping the future of cancer care

video-image

Michael Diaz, MD, regarding high priority policy initiatives for COA

video-image

Michael Diaz, MD, articulates his goals for the coming year as president of COA

video-image

Michael Diaz, MD, shares exciting updates from the 2019 Community Oncology Conference

video-image

Stephen Schleicher, MD, MBA, regarding participation in a two-sided risk model

video-image

Stephen Schleicher, MD, MBA, discusses participation in the Oncology Care Model

video-image

Stephen Schleicher, MD, MBA, on the challenges associated with value-based care

video-image

James Hamrick, MD, on how practicing oncologists and the FDA could utilize real world evidence

video-image

James Hamrick, MD, explains how real world evidence figures into clinical trial design

video-image

James Hamrick, MD, discusses the value of real world evidence data

video-image

Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care

video-image

Ricky Newton on how COA has helped practices keep their in-office dispensing in network

video-image

Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices

video-image

Ted Okon, MBA, considers what can be done to encourage PBM transparency

video-image

Ted Okon, MBA, on what COA is doing to help community oncology practices

video-image

Ted Okon, MBA, regarding the key issues faced by community oncologists today

video-image

Ted Okon, MBA, offers his interpretation of the Practice Impact Report released at COA 2018

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Robert Rifkin, MD, tells us about biosimilar pricing and reimbursement

video-image

Robert Rifkin, MD, lists those biosimilars now approved or close to approval

video-image

Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists

video-image

Robert Rifkin, MD, on the impact of extrapolation and interchangeability on biosimilar use

video-image

Robert Rifkin, MD, tells us about the regulatory pathway for gaining FDA approval of a biosimilar

video-image

Robert Rifkin, MD, explains the key features of biosimilars

video-image

Rebecca A. Kirch, JD, explains how CMS & commercial insurers have embraced palliative care

video-image

Rebecca A. Kirch, JD, on factors that should be considered before starting a palliative care program

video-image

Rebecca A. Kirch, JD, discusses the impact of high quality palliative care programs

video-image

Ray Page, DO, PhD, on what oncology practices should be doing to advocate for their patients

video-image

Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care

video-image

Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM

video-image

Nate Brown speculates on the future of MIPS and oncology practices

video-image

Nate Brown regarding the steps a practice should take to get started on MIPS

video-image

Nate Brown explains why a practice should participate in MIPS

video-image

Miriam Atkins, MD, elaborates on what cancer patients can do to advocate for themselves

video-image

Miriam Atkins, MD, considers what COA is doing to educate patients on their cancer care

video-image

Michael Kolodziej, MD, FACP, on the legislative issues most salient to community oncologists today

video-image

Michael Kolodziej, MD, FACP, considers how the move from volume to value impacts community oncology

video-image

Mark Fendrick, MD, on cost containment strategies that work best in value-based insurance design

video-image

Mark Fendrick, MD, on designing incentives when dealing with expensive cancer therapies

video-image

Mark Fendrick, MD, considers the challenges associated with value-based insurance design

video-image

Mark Fendrick, MD, provides examples of value-based insurance design in oncology care

video-image

Mark Fendrick, MD, explains the motivation behind value-based insurance design

video-image

Michael Diaz, MD, considers what PBMs can do to help community oncology

video-image

Michael Diaz, MD, discusses what cancer patients can do to advocate for themselves

video-image

Michael Diaz, MD, shares what COA is doing to educate cancer care patients

video-image

Michael Diaz, MD, tells us about the goals of the patient initiative on Capital Hill at COA 2018

video-image

Kathy Oubre on how lobbying has helped influence the community oncology agenda

video-image

Kathy Oubre outlines some of the lobbying tactics that community oncology practices should adopt

video-image

Kathy Oubre explains why it’s important for community oncology practices to participate in lobbying

video-image

Jonathan E. Levitt, Esq. explains why oncology practices should be aware of co-pay aggregators

video-image

Jonathan E. Levitt, Esq. on the importance of PBM transparency

video-image

Jonathan E. Levitt, Esq. discusses the problems that exist between PBMs and oncology providers

video-image

Jonathan E. Levitt, Esq. provides an update on the oncology landscape from a legal perspective

video-image

Jeff Mortier explains what can be done to encourage PBM transparency

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Jeff Mortier discusses some of the issues presented at Hill Day during COA 2018

video-image

Fred Schnell, MD, compares OCM 2.0 and OCM 1.0

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Fred Schnell, MD, considers why practice transformation is often difficult in oncology

video-image

Debra Patt, MD, MPH, MBA, regarding advances in next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, considers reimbursement & coverage of CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on what community oncologists should know before prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, explains the benefits & challenges associated with prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, analyzes the logistics associated with CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on CMS’s National Coverage Determination & next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, regarding the reliability of next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, on the progress being made in next-generation sequencing

video-image

Bud Pierce, MD, describes how Oregon Oncology Specialists has evolved

video-image

Bud Pierce, MD, explains what his practice is doing to alleviate financial toxicity

video-image

Bud Pierce, MD, regarding the doctor-patient relationship in today’s oncology landscape

video-image

Brian DeLashmutt considers cost of care in hospital-based & community oncology settings

video-image

Brian DeLashmutt shares details of his own cancer care experience

video-image

Houston Holmes, MD, MBA, FACP, provides perspective on reimbursement & coverage of CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on what community oncologists should know about prescribing CAR-Ts

video-image

Houston Holmes, MD, MBA, FACP, regarding the benefits & challenges of prescribing CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on the logistics associated with CAR-T therapies

video-image

Suanne Gersdorf, FACHE, MSB, on the impact of value-based care and easing financial toxicity

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Suanne Gersdorf, FACHE, MSB, considers how EHR data can be used to improve outcomes

video-image

Suanne Gersdorf, FACHE, MSB, on how oncology practices have become more efficient in utilizing APNs

video-image

Suanne Gersdorf, FACHE, MSB, regarding the importance of embracing APNs

video-image

Harry “Mac” Barnes, MD, explains the benefits of training advanced practitioners

video-image

Harry “Mac” Barnes, MD, elaborates on the role of advanced care providers in cancer patient care

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Charles Loprinzi, MD, on the importance of physician communication in making an end of life plan

video-image

Charles Loprinzi, MD, considers the best approach to preventing nausea during chemotherapy

video-image

Charles Loprinzi, MD, discusses managing nasal vestibulitis during cancer treatment

video-image

Charles Loprinzi, MD, explains the role of palliative and supportive care in medical oncology

video-image

Erin Stevens, MD, on how treating sexual dysfunction fits into a symptom management plan

video-image

Erin Stevens, MD, elaborates on interventions to address sexual dysfunction in cancer patients

video-image

Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

video-image

Erin Stevens, MD, considers the prevalence of sexual dysfunction in advanced cancer patients

video-image

Sandip Patel, MD, discusses some solutions for managing toxicities associated with immunotherapies

video-image

Sandip Patel, MD, considers immunotherapy combinations and the likelihood of severe adverse events

video-image

Sandip Patel, MD, on identifying patient types likely to experience immune-related adverse events

video-image

Sandip Patel, MD, describes the prominent safety challenges with administration of immunotherapies

video-image

Sandip Patel, MD, on the role of immunotherapies when treating cancer near end of life

video-image

Sharon Bober, PhD, describes how treating sexual dysfunction fits into a symptom management plan

video-image

Sharon Bober, PhD, considers intervention methods to address sexual dysfunction in cancer patients

video-image

Sharon Bober, PhD, explains how sexual health fits into quality of life in patient-reported outcomes

video-image

Sharon Bober, PhD, elaborates on the prevalence of sexual dysfunction in advanced cancer patients

video-image

Timothy Morgenthaler, MD, on what drugs seem to be most effective when treating insomnia

video-image

Timothy Morgenthaler, MD, discusses prevention of insomnia in susceptible advanced cancer patients

video-image

Timothy Morgenthaler, MD, regarding the prevalence of insomnia when treating advanced cancer

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on the role of a medical home and palliative care

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on how palliative care looks in a rural practice setting

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on innovations that support the integration of palliative care

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, discusses integrating palliative care in cancer centers

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on incorporating palliative care at Billings Cancer Center

video-image

Rudolph Navari, MD, considers how treating nausea fits into a broader symptom management plan

video-image

Rudolph Navari, MD, regarding effective drugs or drug regimens when treating CINV in advanced cancer

video-image

Rudolph Navari, MD, on identifying advanced cancer patients more likely to experience severe nausea

video-image

Rudolph Navari, MD, describes the prevalence of nausea when treating advanced cancer

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Skip Burris, MD, offers his opinion on liquid biopsies as the new standard of care

video-image

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

video-image

Ray Bailey on novel adherence approaches to help patients stay on oral cancer agents

video-image

Ray Bailey explains how he works with payers to dispense oral cancer agents to patients

video-image

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

video-image

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

video-image

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

video-image

Joseph Lynch, MD, on Professional Services Agreements versus full employment with a hospital system

video-image

Joseph Lynch, MD, evaluates how patients react to the hospital setting versus community setting

video-image

Joseph Lynch, MD, shares how moving to the hospital setting influences quality of care

video-image

Joseph Lynch, MD, on how community oncologists can work closer with their local hospital system

video-image

Joseph Lynch, MD, describes his practice's current arrangement with St. Francis Health System

video-image

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

video-image

Bobby Green, MD, describes how oncologists can leverage data to better utilize claims data

video-image

Bobbi Buell offers advice to practices on how to guarantee good coding

video-image

Bobbi Buell on the implications of mistakes in coding

video-image

Patrick Cobb, MD, describes moving to an outpatient setting and the impact on cancer care

video-image

Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream

video-image

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

video-image

Skip Burris, MD, discusses the importance of oral oncolytics in today’s market place

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Bruce Feinberg, DO, describes how Cardinal Health is changing the world of oncology

video-image

Bruce Feinberg, DO, shares his special interest in value-based care

video-image

Bruce Feinberg, DO, comments on site of care and its impact on cancer economics

video-image

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

video-image

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

video-image

Jeff Patton, MD, describes the relationship between oral cancer agents and practice economics

video-image

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

video-image

Jeff Patton, MD, reflects on how his practice manages the transition to value-based care

video-image

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

video-image

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

video-image

Robert Baird Jr. on forging beneficial relationships with other cancer stakeholders

video-image

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

video-image

Edward Li on how clinical pathways are making progress towards their original goals

video-image

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

video-image

Edward Li considers how comfortable medical oncologists and patients should be with biosimilars

video-image

Edward Li provides examples of oncology targeting biosimilars that are nearing approval

video-image

Edward Li outlines the legal challenges surrounding biosimilars and market entry

video-image

Edward Li on the status of the biosimilars regulatory pathway

video-image

Ted Okon lists key takeaways from the 2017 COA meeting

video-image

Ted Okon describes how PBMs affect oncologists and cancer patients

video-image

Ted Okon shares the latest news on the 340B policy

video-image

Ben Jones gives advice to practices interested in advocating for community oncology

video-image

Ben Jones shares what McKesson Specialty Health is doing to help community oncologists thrive

video-image

Ben Jones on the hot policy topics impacting the delivery of quality cancer care

video-image

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

video-image

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

video-image

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

video-image

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

video-image

Debra Patt, MD, on technological advances in cancer care and community oncology

video-image

Debra Patt, MD, shares how community oncology has contributed to advances in population health

video-image

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

video-image

Miriam Yvette Jones Atkins, MD, explains how the COA Patient Advocacy Network makes a difference

video-image

Miriam Yvette Jones Atkins, MD, on involving patients in the COA Patient Advocacy Network

video-image

Miriam Yvette Jones Atkins, MD, on how the COA Patient Advocacy Network benefits patients

video-image

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

video-image

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

video-image

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

video-image

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

video-image

James Hamrick, MD, reflects on how the EMR can overcome quality reporting challenges

video-image

James Hamrick, MD, debriefs physicians on how to be more efficient in their workflow

video-image

James Hamrick, MD, on how practices can succeed in value-based care by managing unstructured data

video-image

Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation

video-image

Lucio Gordan, MD, on how community oncology practices can utilize their own data

video-image

Lucio Gordan, MD, reflects on how he sees community oncology using big data

video-image

Matt Farber elaborates on how specialty pharmacies work with payers to help deliver cancer care

video-image

Matt Farber describes how specialty pharmacies differ

video-image

Matt Farber provides insight on the evolution of specialty pharmacies

video-image

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

video-image

Skip Burris, MD, offers his opinion on searching for rare mutations

video-image

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

video-image

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

video-image

Bobbi Buell explains how practices can avoid the most common mistakes in billing

video-image

Skip Burris, MD, offers his opinion on molecular profiling patients

video-image

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

video-image

Brad Prechtl offers his opinion on how size influences community oncology practices

video-image

Brad Prechtl explains how “shared savings” works between FCS and a local payer

video-image

Brad Prechtl on the keys to success for Florida Cancer Specialists

video-image

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

video-image

William Harwin, MD, explains how he manages the quality measures required for OCM

video-image

William Harwin, MD, on working with local payers to deliver quality care

video-image

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

video-image

William Harwin, MD, describes the shift from fee for service to value-based care

video-image

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

video-image

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

video-image

Barbara McAneny, MD, on what she would like to accomplish if she became president of the AMA

video-image

Barbara McAneny, MD, discusses how the AMA is helping physicians working in all practice settings

video-image

Ricky Newton provides an example of how a PBM is impacting cancer patient care

video-image

Ricky Newton describes the paper COA is releasing on patient experiences with PBMs

video-image

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

video-image

Ricky Newton describes what happened with CVS last year and how COPA is working with CVS today

video-image

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

video-image

Bobby Green, MD, explains how he defines big data

video-image

Barbara McAneny, MD, explains how the AMA and community oncology should interact

video-image

Barbara McAneny, MD, discusses novel payer initiatives she finds interesting

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, discusses the practicality of the value tool at Dayton Physicians Network

video-image

Perspective on the NCCN Evidence Blocks by Charles Bane, MD

video-image

Perspective on the ASCO Value Framework by Charles Bane, MD

video-image

Bruce Gould, MD, explains how the value tools could be used in the community practice setting

video-image

Perspective on the NCCN Evidence Blocks provided by Bruce Gould, MD

video-image

Perspective on the ASCO Value Framework provided by Bruce Gould, MD

video-image

Bruce Gould, MD, explains ASCO’s policy toward clinical pathways at this time

video-image

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

video-image

Bruce Gould, MD, describes the concerns his practice has with clinical pathways

video-image

Barbara McAneny, MD, explains why CMS implemented the ASP experiment

video-image

Barbara McAneny, MD, informs as to what practices should know about MACRA

video-image

Barbara McAneny, MD, reviews the COME HOME project’s influence on the Oncology Care Model

video-image

Barbara McAneny, MD, discusses COME HOME’s adaptability to other community oncology practices

video-image

Barbara McAneny, MD, talks about the COME HOME project’s impact on community oncology practices

video-image

Barbara McAneny, MD, discusses the COME HOME project’s future

video-image

Jeff Patton, MD, explains what could happen if the CMS ASP Experiment proceeds as planned by CMS

video-image

Jeff Patton, MD, explains how Tennessee Oncology benefits from being a member of COA

video-image

Jeff Patton, MD, explains why the 2016 COA meeting is a must attend meeting

video-image

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

video-image

Deborah Patt, MD, shares her concerns about the CMS ASP Experiment and Part B reimbursement

video-image

Deborah Patt, MD, tells us how chemotherapy costs figure into total care

video-image

Deborah Patt, MD, points out how oncologists can reduce cancer costs

video-image

Deborah Patt, MD, details surprising outcomes from a recent cost study

video-image

Deborah Patt, MD, looks at the bigger expense drivers in cancer care

video-image

David Eagle, MD, gives his opinion on the CMS ASP Experiment

video-image

David Eagle, MD, enumerates what oncologists can do to bring cancer costs down

video-image

David Eagle, MD, lists outcomes from the COA study surprising to oncologists

video-image

David Eagle, MD, details the bigger expenses driving up cancer care costs based on the COA study

video-image

David Eagle, MD, compares costs for treating cancer vs. non-cancer based on the COA study

video-image

David Eagle, MD, talks about COA’s Cost Drivers of Cancer Care study

video-image

Bhuvana Sagar, MD, tells us about the Cigna medical home for oncologists

video-image

Bhuvana Sagar, MD, discusses Cigna’s work with oncologists to find alternative payment models

video-image

Bhuvana Sagar, MD, explains the need for alternative payment models in oncology

video-image

Barry Russo explains the impact of the CMS ASP Experiment

video-image

Practices need to get ready to replace buy and bill explains Barry Russo

video-image

Bruce Gould, MD, explains the characteristics that makes a practice ready for OCM

video-image

Brad Prechtl briefs us on his concerns with the“Medicare Experiment” and its impact

video-image

Brad Prechtl tells how his practice is working to improve cancer care

video-image

Brad Prechtl talks about how community oncology practices can survive today

video-image

Brad Prechtl explains the benefits of community oncology practices joining forces

video-image

Bhuvana Sagar, MD, forecasts the possible Cigna adoption of a Medicare OCM model

video-image

Participation in the Oncology Care Model (OCM) as explained by Barry Russo

video-image

Barry Russo explains how important it is to embrace alternative payment models

video-image

Barry Russo tells us how his practice is getting ready for value-based care

video-image

Patrick Cobb, MD, FACP, looks ahead to treatment innovations that will make a difference

video-image

Patrick Cobb, MD, FACP, talks about some exciting, recent innovations in cancer treatment

video-image

Michael Diaz, MD, talks about working with payers to add quality and value

video-image

Michael Diaz, MD, discusses the challenges in adopting quality and value measures

video-image

Michael Diaz, MD, talks about why the community oncology setting is the best value for patients

video-image

John Fox, MD, predicts if the ASCO Value Framework or NCCN Evidence Blocks will impact drug spend

video-image

John Fox, MD, talks about how Priority might use the ASCO and NCCN value tools

video-image

John Fox, MD, talks about the new value tools from ASCO and NCCN

video-image

John Fox, MD, provides perspective on collaborating with providers on clinical pathways

video-image

A look at cancer clinical pathways with Charles Bane, MD

video-image

Ricky Newton, CPA, updates us on COPA

video-image

Ricky Newton, CPA, details how COPA’s website helps practice managers, pharmacists, and patients

video-image

Ricky Newton, CPA, explains the purpose of COPA’s new In-House and Specialty Pharmacies brief

video-image

Ricky Newton, CPA, tells us what follow up to expect from COPA’s new brief

video-image

Robert Baird fills us in on the Value-Based Purchasing Modifier's impact on Dayton

video-image

Robert Baird details how practices can prepare for the Value-Based Purchasing Modifier and MIPS

video-image

Robert Baird explains how Dayton physicians and payers are collaborating on APMs

video-image

Robert Baird answers questions on Dayton’s participation in the Oncology Care Model

video-image

Skip Burris, MD, outlines the scope of cancer clinical trials at SCRI

video-image

Skip Burris, MD, talks about how CAR-Ts work, and the trials taking place at SCRI

video-image

Skip Burris, MD, looks at the promise of immunotherapies in combination

video-image

Skip Burris, MD, explains goals and outcomes of the My Pathway trial

video-image

Skip Burris, MD, reflects on the promise and concerns with liquid biopsies

video-image

Ted Okon tells us why the CNS ASP Experiment is a bad idea

video-image

Embrace alternative payment models explains Ted Okon

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, explains the role an in-house pharmacy plays in the quality equation

video-image

Sue Naeyaert predicts whether we will see more cancer biosimilars soon

video-image

Sue Naeyaert tells us what to expect in pricing biosimilars

video-image

A look at the expansion of a biosimilar’s FDA label with Sue Naeyaert

video-image

Sue Naeyaert explains the proposed reimbursement of biosimilars by CMS

video-image

Skip Burris, MD, discusses how precision medicine is changing cancer treatment

video-image

Sue Naeyaert provides her vision of the biosimilar products in development

video-image

Todd Murphree briefs us on ACHC’s oncology accreditation process

video-image

Todd Murphree, PharmD, discusses how ACHC accreditation benefits his practice

video-image

Ted Okon discusses the sessions that stand out at this year's annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon provides an overview of the Cost Drivers in Cancer Care study

video-image

Mary Kruczynski speaks to those who were unable to attend the 2016 Annual COA meeting

video-image

Mary Kruczynski tells us how the 2016 Annual COA meeting benefits health care providers

video-image

Mary Kruczynski reflects on highlights from COA

video-image

Lucio Gordan, MD, lists takeaways from COA that can benefit his own practice

video-image

Lucio Gordan, MD, debriefs providers who didn’t attend on highlights from COA

video-image

Lucio Gordan, MD, reflects on key messages from this year’s COA

video-image

Jeff Vacirca, MD, explains the relevance of the COA/Milliman study to his practice

video-image

Jeff Vacirca, MD, talks about what his community oncology practice is doing to survive

video-image

Jeff Patton, MD, explains how his practice is working to develop alternative payment models

video-image

COA is helping community oncologists by fighting the CMS ASP Experiment by Jeff Patton, MD

video-image

Robert Baird tells us what MIPS are and how practices might use them

video-image

Patrick Cobb, MD, discusses treatment innovations and managing patient’s expectations

video-image

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

video-image

David Eagle, MD, compares treatment costs in different settings

video-image

Mary Kruczynski tells us how the Cost Drivers in Cancer Care study was developed

video-image

Managing patients on regorafenib including adverse events